Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

High levels of the onco-protein Gfi-1 accelerate T-cell proliferation and inhibit activation induced T-cell death in Jurkat T-cells

Abstract

Gfi-1 is a nuclear zinc finger protein with the activity of a transcriptional repressor and the ability to predispose for the development of T-cell lymphoma when expressed constitutively at high levels. Whereas thymic T-cell precursors express endogenous Gfi-1, mature peripheral T-cells lack Gfi-1 but upregulate its expression transiently after antigenic stimulation and activation of Erk1/2 demonstrating a role of Gfi-1 in T-cell activation. Here we show that constitutive expression of Gfi-1 accelerates S phase entry of primary, resting T-cells upon antigenic stimulation. In addition, high level Gfi-1 expression inhibits phorbol ester induced G1 arrest and activation induced cell death in Jurkat T-cells. We demonstrate that these effects of Gfi-1 concur with lower absolute levels and hyperphosphorylation of the pocket protein pRb. Moreover, phorbol ester induced expression of the negative cell cycle regulator p21WAF1 is blocked in the presence of Gfi-1. These findings suggest that Gfi-1 contributes to T-cell lymphomagenesis by overriding a late G1 cell cycle checkpoint which controls activation induced death and S phase entry of T-cells.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  • Brehm A, Miska E, Reid J, Bannister A, Kouzarides T . 1999 Br. J. Cancer 80: 38–41

  • Firpo EJ, Koff A, Solomon MJ, Roberts JM . 1994 Mol. Cell. Biol. 14: 4889–4901

  • Gilks CB, Bear SE, Grimes HL, Tsichlis PN . 1993 Mol. Cell. Biol. 13: 1759–1768

  • Green DR, Scott DW . 1994 Curr. Opin. Immunol. 6: 476–487

  • Grimes HL, Chan TO, Zweidler-McKay PA, Tong B, Tsichlis PN . 1996 Mol. Cell. Biol. 16: 6263–6272

  • Harbour JW, Dean DC . 2000 Genes Dev. 14: 2393–2409

  • Jones LA, Chin LT, Longo DL, Kruisbeek AM . 1990 Science 250: 1726–1729

  • Kabelitz D, Pohl T, Pechhold K . 1993 Immunol. Today 14: 338–339

  • Karas M, Zaks TZ, Liu JL, LeRoith D . 1999 Mol. Cell. Biol. 10: 4441–4450

  • Karsunky H, Geisen C, Schmidt T, Haas K, Zevnik B, Gau E, Möröy T . 1999 Oncogene, 18: 7816–7824

  • Lenardo MJ, Boehme S, Chen L, Combadiere B, Fisher G, Freedman M, McFarland H, Pelfrey C, Zheng L . 1995 Int. Rev. Immunol. 13: 115–134

  • Li QS, Tanaka S, Kisenge RR, Toyoda H, Azuma E, Komada Y . 2000 Eur. J. Immunol. 30: 3329–3337

  • Lissy NA, van Dyk LF, Becker-Hapak M, Vocero-Akbani A, Mendler JA, Dowdy SF . 1999 Immunity 8: 57–65

  • Liu S, Cowell JK . 2000 Ann. Hum. Genet. 64: 83–86

  • Macian F, Lopez-Rodriguez C, Rao A . 2001 Oncogene 20: 2476–2489

  • Muller H, Helin K . 2000 Biochim. Biophys. Acta. 1470: M1–M12

  • Nourse J, Firpo E, Flanagan WM, Coats S, Polyak K, Lee MH, Massague J, Crabtree GR, Roberts JM . 1994 Nature 372: 570–573

  • Rocha B, von Boehmer H . 1991 Science 251: 1225–1228

  • Rödel B, Tavassoli K, Karsunky H, Schmidt T, Bachmann M, Shaper F, Heinrich P, Shuai K, Elsässer HP, Möröy T . 2000 EMBO J. 19: 5845–5855

  • Scheijen B, Jonkers J, Acton D, Berns A . 1997 J. Virol. 71: 9–16

  • Schmidt T, Zörnig M, Beneke R, Möröy T . 1996 Nucl. Acids Res. 24: 2528–2534

  • Schmidt T, Karsunky H, Gau E, Zevnik B, Elsässer HP, Möröy T . 1998 Oncogene 17: 2661–2667

  • Stankunas K, Graef IA, Neilson JR, Park SH, Crabtree GR . 1999 Cold Spring Harb. Symp. Quant. Biol. 64: 505–516

  • Wells AD, Gudmundsdottir H, Turka CA . 1997 J. Clin. Invest. 100: 3173–3183

  • Ziegler SF, Ramsdell F, Alderson MR . 1994 Stem Cells 12: 456–465

  • Zörnig M, Schmidt T, Karsunky H, Grzeschiczek A, Möröy T . 1996 Oncogene 12: 1789–1801

  • Zweidler-McKay PA, Grimes HL, Flubacher MM, Tsichlis PN . 1996 Mol. Cell Biol. 16: 4024–4034

Download references

Acknowledgements

This work was supported by the Deutsche Forschungsgemeinschaft (grant Mo 435/9-1, 9-3), the ‘Fonds der chemischen Industrie’, by the European Community Framework 5 Program and the ‘IFORES Program’ of the University of Essen Medical School.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Tarik Möröy.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Karsunky, H., Mende, I., Schmidt, T. et al. High levels of the onco-protein Gfi-1 accelerate T-cell proliferation and inhibit activation induced T-cell death in Jurkat T-cells. Oncogene 21, 1571–1579 (2002). https://doi.org/10.1038/sj.onc.1205216

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205216

Keywords

This article is cited by

Search

Quick links